CONCLUSION
Recurrent uLMS are a rare group of tumors with an aggressive behavior and poor outcomes. The current study shows that secondary cytoreductive surgery is an important treatment choice for these patients and seems to have benefited patients. Time to fist recurrence within 12 months is an independent predictor of decreased 5-year OS in SCS subgroup. It’s important to identify the suitable candidate for SCS. A prospective large study is warranted to validate these findings.